News and Events - Cardionovum®

Latest press release

Oct 10, 2016

Globally first patient treated with LEGFLOW 018 in MOL, Belgium

Dr. Berghmans and Dr. van Bouckenooghe were the worldwide first users of the LEGFLOW 018 on a Patient with CLI disease. The product was used in BtK and showed excellent performance. In addition the patient received a DCB therapy with our LEGFLOW OTW in the SFA as well.

Learn more >> Globally first patient treated with LEGFLOW 018 in MOL, Belgium

June 01, 2016

CARDIONOVUM Announces Enrollment Completion of RAPID Trial

CARDIONOVUM GmbH today announced the completion of enrollment of the RAPID trial. Results will be used to further support the safety and effectiveness of CARDIONOVUM’s Legflow^® drug-coated balloon (DCB).

Learn more >> CARDIONOVUM Announces Enrollment Completion of RAPID Trial

Mar 30, 2016

Cardionovum announces enrollment of first patient in MAGNIFICENT trial

CARDIONOVUM GmbH, a medical technology company developing and commercializing innovative medical devices such as drug-coated balloons and drug-eluting stents for the treatment of coronary and peripheral artery disease, announced today the enrollment of the first patient in the MAGNIFICENT trial.

Learn more >> Cardionovum announces enrollment of first patient in MAGNIFICENT trial

Feb 17, 2016

RESTORE clinical study results on in-stent restenosis.

Cardionovum experiences increase in demand for its innovative, and next generation „RESTORE Paclitaxel-releasing coronary balloon dilatation catheter.“ The American Journal of Cardiology, issue December 2015, published study results on the efficacy and safety of Paclitaxel coated balloon catheters for the treatment of in-stent restenosis in high risk patients. The RESTORE DEB showed significant superiority with lowest incidence of restenosis, if compared to other contemporary coronary DEBs.

Learn more >> RESTORE clinical study results on in-stent restenosis.

Feb 01, 2016

Cardionovum at LINC 2016

Dr. Jean Paul de Vries (PI) presented the patient study results of the multi-center randomized RAPID trial.

Learn more >> Cardionovum at LINC 2016

Dec 04, 2015

Early APERTO patient results look promising.

Cardionovum prepares for a first international publication on 6-12 months FU patient results from the ongoing APERTO clinical study program. The APERTO Paclitaxel-releasing high pressure shunt balloon dilatation catheter was exclusively designed to treat shunt stenosis of hemodialysis patients.

Learn more >> Early APERTO patient results look promising.